New Delhi, April 28 -- The Delhi High Court on Tuesday ordered Dr. Reddy's Laboratories to give an undertaking that it will not communicate or promote its generic semaglutide drug under the brand name "Olymviq" to doctors, patients or traders, after Novo Nordisk alleged continued use of the mark, which sounds similar to its flagship brand Ozempic, in violation of earlier court directions.

The direction came as the Danish drugmaker moved a fresh plea accusing Dr. Reddy's of breaching its undertaking to discontinue the mark and transition to a new brand, Olymra, in their ongoing trademark dispute.

Justice Jyoti Singh, who heard the matter, expressed displeasure over the alleged non-compliance with her March 30 order. "I say this with grea...